Axon Enterprise, Inc $AXON Shares Acquired by GM Advisory Group LLC

GM Advisory Group LLC lifted its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 61.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,158 shares of the biotechnology company’s stock after buying an additional 1,575 shares during the period. GM Advisory Group LLC’s holdings in Axon Enterprise were worth $1,766,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in Axon Enterprise during the 4th quarter valued at about $480,000. NewEdge Advisors LLC lifted its stake in Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after purchasing an additional 668 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after purchasing an additional 157 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of Axon Enterprise by 40.6% during the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock worth $3,646,000 after purchasing an additional 2,003 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in shares of Axon Enterprise during the 2nd quarter worth approximately $284,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $500.00, for a total transaction of $5,000,000.00. Following the transaction, the chief executive officer directly owned 3,050,997 shares in the company, valued at $1,525,498,500. This represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $478.97, for a total value of $270,139.08. Following the transaction, the director owned 3,632 shares of the company’s stock, valued at approximately $1,739,619.04. This represents a 13.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 48,989 shares of company stock worth $24,090,083 in the last three months. Company insiders own 4.20% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $597.04 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The firm has a market cap of $48.12 billion, a PE ratio of 239.78, a price-to-earnings-growth ratio of 12.18 and a beta of 1.38. The company has a 50-day moving average of $437.68 and a two-hundred day moving average of $482.40. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The business had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.90 million. During the same period in the previous year, the firm earned $1.47 EPS. The business’s revenue was up 33.7% on a year-over-year basis. On average, analysts predict that Axon Enterprise, Inc will post 1.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. TD Cowen cut their price target on Axon Enterprise from $950.00 to $825.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Zacks Research raised Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Morgan Stanley set a $600.00 target price on Axon Enterprise in a report on Thursday, May 7th. Barclays cut their target price on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, The Goldman Sachs Group set a $535.00 price target on Axon Enterprise in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and an average price target of $712.75.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.